Last reviewed · How we verify
NCT05734053: NOFRETETE
Nilotinib for Patients With Chronic Myeloid Leukemia in First Line and Any Subsequent Line
trial testing Nilotinib in Chronic Myeloid Leukemia in 222 participants. Completed in 8 September 2022.
8 September 2022
Quick facts
| Lead sponsor | Novartis Pharmaceuticals |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 222 |
| Start date | 28 June 2016 |
| Primary completion | 8 September 2022 |
| Estimated completion | 8 September 2022 |
| Sites | 77 locations across Germany |
Drugs / interventions tested
- Nilotinib (NILOTINIB) — full drug profile →
Conditions studied
- Chronic Myeloid Leukemia — all drugs for Chronic Myeloid Leukemia →
Sponsor
Novartis Pharmaceuticals — full company profile →
Who can join
18 and older, any sex, with Chronic Myeloid Leukemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This was a non-interventional observational study within the routine chronic myeloid leukemia treatment practice; no further tests were required apart from the assessments routinely performed for Chronic myeloid leukemia patients treated with nilotinib.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05734053
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Nilotinib
Trials testing the same drug.
- NCT07493408 — Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of · Phase 2 · not yet recruiting
- NCT05456191 — A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 · Phase 3 · active not recruiting
- NCT05185947 — Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Ap · Phase 2 · active not recruiting
- NCT04877522 — Asciminib Roll-over Study · Phase 4 · recruiting
- NCT04971226 — A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP · Phase 3 · active not recruiting
Other recruiting trials for Chronic Myeloid Leukemia
Currently open trials in the same condition.
- NCT06817720 — Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chroni · Phase 2 · recruiting
- NCT07238712 — Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies · Phase 2 · recruiting
- NCT06453902 — TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients · Phase 2 · recruiting
- NCT06390306 — The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP · recruiting
- NCT06355583 — Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial · Phase 2 · recruiting
Other Novartis Pharmaceuticals trials
Trials by the same sponsor.
- NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
- NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
- NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
- NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
- NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05734053 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
- Last refreshed: 21 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05734053.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing